---
document_datetime: 2025-08-04 10:54:51
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/rezolsta-epar-all-authorised-presentations_en.pdf
document_name: rezolsta-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7431775
conversion_datetime: 2025-12-28 10:42:37.816784
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA(EU) number   | (Invented) name   | Strength      | Pharmaceutical Form   | Route of Administration   | Immediate Packaging   | Pack size   |
|-----------------|-------------------|---------------|-----------------------|---------------------------|-----------------------|-------------|
| EU/1/14/967/001 | REZOLSTA          | 800 mg/150 mg | Film-coated tablet    | Oral use                  | bottle (HDPE)         | 30 tablets  |
| EU/1/14/967/002 | REZOLSTA          | 675 mg/150 mg | Film-coated tablet    | Oral use                  | bottle (HDPE)         | 30 tablets  |